Anticipating Pixantrone Approval, Cell Therapeutics Adopts A "Poison Pill" Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
The shareholder rights plan includes a provision that is intended to forestall a hostile takeover bid.